Get the Stockscreener App
35.39
1.72%
-0.62
After Hours:
34.99
-0.40
-1.13%
Royalty Pharma Plc stock is traded at $35.39, with a volume of 1.76M.
It is down -1.72% in the last 24 hours and down -2.67% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$36.01
Open:
$35.8
24h Volume:
1.76M
Relative Volume:
0.47
Market Cap:
$15.30B
Revenue:
$2.31B
Net Income/Loss:
$1.66B
P/E Ratio:
15.39
EPS:
2.3
Net Cash Flow:
$827.02M
1W Performance:
-2.05%
1M Performance:
-2.67%
6M Performance:
+10.77%
1Y Performance:
+26.30%
1-Day Range:
$35.23
$35.98
1-Week Range:
$35.23
$36.48
52-Week Range:
$24.05
$38.00
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
35.39 | 15.57B | 2.31B | 1.66B | 827.02M | 2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty pharma projects 6-12% growth in 2025 portfolio receipts with $2B share buyback plan - MSN
What’s the recovery path for long term holders of Royalty Pharma plcJuly 2025 Rallies & Real-Time Market Trend Scan - newser.com
Royalty Pharma plc (RPRX) Stock Analysis: Unveiling a 23.59% Upside Potential in the Biotech Royalty Space - DirectorsTalk Interviews
Why retail investors pile into Royalty Pharma plc stockJuly 2025 Spike Watch & Real-Time Stock Entry Alerts - newser.com
Is this a good reentry point in Royalty Pharma plcQuarterly Investment Review & AI Forecasted Stock Moves - newser.com
Royalty Pharma PLC $RPRX Shares Sold by Board of the Pension Protection Fund - MarketBeat
Inspire Investing LLC Buys 22,436 Shares of Royalty Pharma PLC $RPRX - MarketBeat
What candlestick patterns are forming on Royalty Pharma plcJuly 2025 Setups & Risk Managed Investment Signals - newser.com
KLP Kapitalforvaltning AS Increases Position in Royalty Pharma PLC $RPRX - MarketBeat
Belpointe Asset Management LLC Purchases New Position in Royalty Pharma PLC $RPRX - MarketBeat
Why Royalty Pharma plc (RPD) stock could rally stronglyJuly 2025 Sector Moves & Risk Controlled Stock Alerts - newser.com
Royalty Pharma To Announce Third Quarter 2025 Financial Results On November 5, 2025 - TradingView
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025 - The Manila Times
Q3 2025 Results Nov 5: Royalty Pharma to Report Results and Host Call/Webcast at 8:00 a.m. ET - Stock Titan
Custom watchlist performance reports with Royalty Pharma plcPortfolio Profit Report & Safe Capital Growth Tips - newser.com
Royalty Pharma (NASDAQ:RPRX) Raised to Buy (B-) at Weiss Ratings - MarketBeat
Is Royalty Pharma plc stock a smart buy before Fed meeting2025 Top Gainers & AI Enhanced Execution Alerts - newser.com
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report? - sharewise.com
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Yahoo Finance
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - sharewise.com
Why Royalty Pharma plc stock is a must watch in 2025Weekly Trading Summary & AI Optimized Trade Strategies - newser.com
Understanding Royalty Pharma plc’s price movementMarket Growth Review & Accurate Technical Buy Alerts - newser.com
A Look at Royalty Pharma’s (RPRX) Valuation Following Imdelltra Royalty Acquisition and Board Enhancement - Sahm
Will Royalty Pharma plc stock see PE expansion2025 Analyst Calls & AI Driven Price Predictions - newser.com
Royalty Pharma collaborates with Biogen for R&D funding - MSN
Royalty Pharma PLC $RPRX Position Increased by Robeco Institutional Asset Management B.V. - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Given Average Rating of "Buy" by Analysts - MarketBeat
11% Of This Royalty Pharma Insider's Holdings Were Sold - 富途牛牛
Will Royalty Pharma's (RPRX) Governance Shift Sharpen Its Edge in Life Sciences Investment? - simplywall.st
The Goldman Sachs Group Initiates Coverage on Royalty Pharma (NASDAQ:RPRX) - MarketBeat
The Best Biotech Stocks to Buy - Morningstar
Goldman Sachs initiates Royalty Pharma stock with Buy rating, $42 target - Investing.com Nigeria
Royalty Pharma : Q3 2025 Pre-Quarterly Results Communication - MarketScreener
Goldman Sachs Initiates Coverage of Royalty Pharma (RPRX) with Buy Recommendation - Nasdaq
Royalty Pharma plc Stock Analysis and ForecastPrice Action Analysis & High Profit Investment Ideas - earlytimes.in
Goldman Sachs Starts Royalty Pharma (RPRX) at Buy, PT $42 - StreetInsider
Royalty Pharma appoints Ted Love as lead independent director By Investing.com - Investing.com Nigeria
We Think Royalty Pharma (NASDAQ:RPRX) Can Stay On Top Of Its Debt - 富途牛牛
Royalty Pharma : Bernstein Healthcare Forum Transcript - MarketScreener
Royalty Pharma appoints Ted Love as lead independent director - Investing.com
Royalty Pharma names Dr. Ted Love as lead independent director - StreetInsider
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):